ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Educational Symposium

Novel Insights into the Diagnosis and Management of Atypical Hemolytic Uremic Syndrome

October 23, 2020 | 01:00 PM - 02:00 PM

Location: Simulive

Session Description

The syndromes of thrombotic microangiopathy (TMA) are a diverse group of clinical disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and target organ injury. Key pathologic features include arteriolar and capillary thrombosis with evidence of endotheliosis and vessel-wall fibrin. Atypical hemolytic uremic syndrome (aHUS), also known as complement-mediated TMA, is a rare, life-threatening disease with strong genetic underpinnings, characterized by uncontrolled complement activation and predominant renal failure. Other TMA syndromes include thrombotic thrombocytopenic purpura (TTP), Shiga-toxin producing Escherichia coli hemolytic uremic syndrome (STEC-HUS), and drug, metabolism, and coagulation-mediated etiologies. The lack of widely available complement assays and genetic testing has posed a diagnostic challenge for clinicians. In addition, there are gaps in knowledge regarding patient selection and administration of anti-complement therapy.

This symposium reviews the pathogenesis, diagnostic criteria, and treatment of aHUS as a complement-mediated TMA. Emerging therapeutic targets and approaches are discussed.

Support is provided by an educational grant from Alexion Pharmaceuticals, Inc.

Learning Objective(s)

  • Define the diagnostic features of aHUS in the context of TMA syndromes
  • Describe the mechanistic rationale and approach to treating aHUS
  • Describe promising emerging biomarkers and therapeutic interventions for aHUS

Learning Pathway(s)

  • Glomerular Diseases

Moderator

  • Ursula C. Brewster, MD

Presentations

  • Introduction
    01:00 PM - 01:10 PM
    Ursula C. Brewster, MD
  • Pathogenesis and Diagnosis of aHUS
    01:10 PM - 01:35 PM
    Bradley P. Dixon, MD, FASN 
  • Approach to the Treatment of aHUS
    01:35 PM - 02:00 PM
    Eric Rondeau, MD, PhD